Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Urologic ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Liquid Biopsy for Cancer: Circulating Tumor Cells, Circulating Free DNA or Exosomes?.Cell Physiol Biochem. 2017; 41: 755-768
- Biological and therapeutic impact of intratumor heterogeneity in cancer evolution.Cancer Cell. 2015; 27: 15-26
- Liquid Biopsy: The Unique Test for Chasing the Genetics of Solid Tumors.Epigenet Insights. 2020; 13 (2516865720904052)https://doi.org/10.1177/2516865720904052
- Circulating tumor cells versus tumor-derived cell-free DNA: rivals or partners in cancer care in the era of single-cell analysis?.Genome Med. 2013; 5: 70
- A Case of Cancer in Which Cells Similar to Those in the Tumours Were Seen in the Blood after Death.Med J Aust. 1869; 14: 146-147
- Nuclear Acids In Human Blood Plasma.C R Seances Soc Biol Fil. 1948; 142 (Les acides nucleiques du plasma sanguin chez l'homme): 241-243
- Spontaneous release of DNA by human blood lymphocytes as shown in an in vitro system.Cancer Res. 1975; 35: 2375-2382
- DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells.Cancer Res. 2001; 61: 1659-1665
- Characterization of the cell-free DNA released by cultured cancer cells.Biochim Biophys Acta. 2016; 1863: 157-165
- Tumor dissemination: an EMT affair.Cancer Cell. 2013; 23: 272-273
- Significance of blood vessel leakiness in cancer.Cancer Res. 2002; 62: 5381-5385
- Circulating tumor cells, disease progression, and survival in metastatic breast cancer.N Engl J Med. 2004; 351: 781-791
- About the possible origin and mechanism of circulating DNA apoptosis and active DNA release.Clin Chim Acta. 2001; 313: 139-142
- Biology, detection, and clinical implications of circulating tumor cells.EMBO Mol Med. 2015; 7: 1-11
- Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer.Clin Cancer Res. 2017; 23: 5437-5445
- Circulating mutant DNA to assess tumor dynamics.Nat Med. 2008; 14: 985-990
- Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis.Cell. 2014; 158: 1110-1122
- Technologies for detection of circulating tumor cells: facts and vision.Lab Chip. 2014; 14: 57-62
- Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases.Clin Cancer Res. 2004; 10: 6897-6904
- A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire.Int J Oncol. 2012; 41: 1241-1250
- Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells.Sci Transl Med. 2013; 5: 179ra47
- Optimization and evaluation of a novel size based circulating tumor cell isolation system.PLoS One. 2015; 10: e0138032
- Integrating liquid biopsies into the management of cancer.Nat Rev Clin Oncol. 2017; 14: 531-548
- Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective.Expert Rev Mol Diagn. 2018; 18: 7-17
- Sensitive tumour detection and classification using plasma cell-free DNA methylomes.Nat Nov. 2018; 563: 579-583
- Cancer statistics.CA Cancer J Clin. 2022; 72: 7-33
- Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer.JCO Precis Oncol. 2019; https://doi.org/10.1200/PO.19.00176
- Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.Clin Cancer Res. 2008; 14: 6302-6309
- Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer.PLoS One. 2020; 15: e0226219
- Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer.Cancer Discovery. 2012; 2: 995-1003
- Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.J Clin Oncol. 2019; 37: 1120-1129
- Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer.J Clin Oncol. 2015; 33: 1348-1355
- Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials.J Clin Oncol. 20 2018; 36: 572-580
- Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.JAMA Oncol. 2016; 2: 1598-1606
- Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition.Cancer Discovery. 2017; 7: 1006-1017
- Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results.J Clin Oncol. 2015; 33: 1356-1363
- Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.Lancet Oncol. 2020; 21: 162-174
- Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer.Eur Urol. 2016; 70: 985-992
- Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer.Nature. 2022; 608: 199-208
- T1 bladder cancer: current considerations for diagnosis and management.Nat Rev Urol. 2019; 16: 23-34
- Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline.J Urol Sep. 2017; 198: 552-559
- The Prognostic Role of Circulating Tumor Cells (CTC) in High-risk Non-muscle-invasive Bladder Cancer.Clin Genitourin Cancer. 2017; 15: e661-e666
- Prognostic significance of survivin-expressing circulating tumour cells in T1G3 bladder cancer.BJU Int. 2010; 106: 710-715
- Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer.BJU Int. 2011; 107: 1668-1675
- Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma.Urology. 2011; 78: 863-867
- Detection of circulating urothelial cancer cells in the blood using the CellSearch System.Cancer. 2007; 109: 1439-1445
- Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer.Eur Urol. 2016; 70: 75-82
- Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.Eur Urol. 2017; 71: 961-969
- Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma.J Clin Oncol. 2019; 37: 1547-1557
- Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.Cancer. 2018; 124: 2115-2124
- Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw. 2022; 20: 71-90
- Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease.Urol Clin North Am. 2003; 30: 843-852
- Detection of circulating tumor cells in peripheral blood of patients with renal cell carcinoma correlates with prognosis.Cancer Epidemiol Biomarkers Prev. 2009; 18: 2190-2194
- Circulating Tumor Cell Composition in Renal Cell Carcinoma.PLoS One. 2016; 11: e0153018
- Monitoring of plasma cell-free DNA in predicting postoperative recurrence of clear cell renal cell carcinoma.Urol Int. 2013; 91: 273-278
- Concentration and Methylation of Cell-Free DNA from Blood Plasma as Diagnostic Markers of Renal Cancer.Dis Markers. 2016; 2016: 3693096
- Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma.Cancer Sci. 2019; 110: 617-628
- The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.Clin Cancer Res. 2018; 24: 3528-3538
- Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications.Oncotarget. 2017; 8: 33614-33620
- Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma.Eur Urol. 2017; 72: 557-564
Article info
Identification
Copyright
© 2022 Published by Elsevier Inc.
